Herein, we developed a QSP model of anti-PD-(L)1 treatments in Balb/c mice bearing CT26 syngeneic tumors to identify sources of variability in preclinical anti-tumor response, and generated hypotheses for potential sources of variability for pre-clinical to clinical translation. The gene discussed is CD274; the disease is neoplasm.